★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Sanofi (SAN) Moat Analysis
Sanofi
SAN · Euronext Paris
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Sanofi is a France-headquartered biopharma company with Q1 2026 net sales of EUR 10.51bn, of which Pharma represented 87.7% and Vaccines 12.3%; it also retains a 48.2% minority stake in Opella. The clearest Pharma barrier is time-limited patent and regulatory exclusivity, led by Dupixent, while the vaccines business requires specialized facilities, validated biological processes and sustained manufacturing investment. June and July approvals for Cenrifki, Tzield, Wayrilz and subcutaneous Sarclisa demonstrate pipeline progress but do not eliminate clinical, safety, reimbursement or patent-cliff risk. Belén Garijo became Chief Executive Officer in May 2026. Q2 results are scheduled for 30 July 2026.
Primary segment
Pharma (Prescription Medicines)
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
3 segments · 7 tags
Updated 2026-07-12
Segments
Pharma (Prescription Medicines)
Branded prescription pharmaceuticals (immunology, rare disease, neurology, oncology, general medicines)
Revenue
87.7%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Vaccines
Human vaccines (pediatric and adult; respiratory and other infectious diseases)
Revenue
12.3%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Opella (Consumer Healthcare - Sanofi minority stake)
Consumer healthcare (OTC medicines and vitamins/minerals/supplements)
Revenue
—
Structure
Competitive
Pricing
moderate
Share
—
Peers
Moat Claims
Pharma (Prescription Medicines)
Branded prescription pharmaceuticals (immunology, rare disease, neurology, oncology, general medicines)
Revenue share is Q1 2026 Pharma sales implied as total net sales (EUR 10,509m) less Vaccines (EUR 1,293m), or EUR 9,216m divided by total net sales. Q1 weights can be seasonal, especially for Vaccines. Source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-23-05-30-00-3279572.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patents and related IP protections are central to sustaining branded economics; when exclusivity weakens, generics and price pressure erode profitability.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent expiry and biosimilar entry
- Adverse IP litigation outcomes
- Compulsory licensing / government intervention
Leading indicators
- Upcoming loss-of-exclusivity timetable for top products
- Biosimilar/generic launches and price erosion rates
- Material IP litigation milestones
Counterarguments
- Most IP moats are time-limited; durable value depends on pipeline replacement
- Large competitors can outspend or out-innovate in key indications
Vaccines
Human vaccines (pediatric and adult; respiratory and other infectious diseases)
Revenue share is Q1 2026 Vaccines sales (EUR 1,293m) divided by total net sales (EUR 10,509m). Q1 weights can understate or overstate seasonal vaccine franchises. Source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-23-05-30-00-3279572.
Capex Knowhow Scale
Supply
Capex Knowhow Scale
Strength
Durability
Confidence
Evidence
Vaccine manufacturing requires specialized facilities, trained staff, validated biological processes and regulatory approval for production-site changes, creating capital and know-how barriers.
Capex Knowhow Scale moat: definition, examples, and stocks
Erosion risks
- Manufacturing scale-up delays or quality issues
- Platform shifts reset established process know-how
- Underutilized dedicated capacity raises unit costs
Leading indicators
- Vaccine supply reliability and batch-release performance
- Manufacturing investment and new facility approvals
- Regulatory inspection outcomes and recalls
Counterarguments
- GSK, Pfizer and other large peers possess comparable manufacturing depth
- Contract manufacturers and acquisitions can shorten a challenger's capability build
Opella (Consumer Healthcare - Sanofi minority stake)
Consumer healthcare (OTC medicines and vitamins/minerals/supplements)
On April 30, 2025, Sanofi announced it closed the sale of a 50.0% controlling stake of Opella to CD&R and retained a 48.2% stake; Opella is described as a top global OTC & VMS player.
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
Consumer health purchasing is highly brand-led; Opella positions around established brands and consumer trust, supporting repeat purchase and shelf presence.
Brand Trust moat: definition, examples, and stocks
Erosion risks
- Private label substitution and retailer bargaining power
- Regulatory changes in OTC labeling/claims
- Brand dilution from quality/safety incidents
Leading indicators
- Brand share trends in top OTC categories
- Price premium vs private label
- Ad spend efficiency and repeat purchase rates
Counterarguments
- Many OTC categories are commoditized and promotion-driven
- Retailers can reallocate shelf space quickly based on margin/velocity
Evidence
DUPIXENT (dupilumab) | Compound: March 2031 with PTE
The filing identifies the US compound-patent term; EU and Japan compound protection extends later.
biosimilars can be a threat to the exclusivity of any biological therapeutics we sell
Sanofi explicitly describes the time-limited nature and erosion mechanism of biologic exclusivity.
including the need for specialized facilities, trained and certified employees, and highly specific raw materials
The filing identifies the specialized inputs and capabilities required for medicines and vaccines manufacturing.
>EUR 1bn invested annually in modernizing and digitizing our Manufacturing & Supply network
Company-reported annual investment quantifies the scale required to maintain its medicines and vaccines network.
Opella stands out through the strength of its brands
Direct statement emphasizing brand strength as a differentiator.
Showing 5 of 6 sources.
Risks & Indicators
Erosion risks
- Patent expiry and biosimilar entry
- Adverse IP litigation outcomes
- Compulsory licensing / government intervention
- Formulary exclusion and reference pricing
- Manufacturing scale-up delays or quality issues
- Platform shifts reset established process know-how
Leading indicators
- Upcoming loss-of-exclusivity timetable for top products
- Biosimilar/generic launches and price erosion rates
- Material IP litigation milestones
- Vaccine supply reliability and batch-release performance
- Manufacturing investment and new facility approvals
- Regulatory inspection outcomes and recalls
Research SAN elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.